Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes | Zendy

Robert H. Eckel | Zendy; Robert R. Henry | Zendy; Patrick Yue | Zendy; Arvinder K. Dhalla | Zendy; Pamela Wong | Zendy; Philip Jochelson | Zendy; Luiz Belardinelli | Zendy; Jay S. Skyler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes

Author(s) -

Robert H. Eckel,

Robert R. Henry,

Patrick Yue,

Arvinder K. Dhalla,

Pamela Wong,

Philip Jochelson,

Luiz Belardinelli,

Jay S. Skyler

Publication year - 2015

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc14-2629

Subject(s) - medicine , ranolazine , glycemic , type 2 diabetes , diabetes mellitus , endocrinology

Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosylated hemoglobin (HbA1c) in subjects with type 2 diabetes. The study prospectively assessed the safety and efficacy of ranolazine in subjects with type 2 diabetes with inadequate glycemic control managed by lifestyle alone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research